Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow K O, Schou C, Løwenstein H
Department of Pediatrics B57, Karolinska Institutet, Huddinge Hospital, Sweden.
J Allergy Clin Immunol. 1995 Dec;96(6 Pt 1):879-85. doi: 10.1016/s0091-6749(95)70223-7.
A 5-year follow-up study was conducted to investigate the duration of the effects of a 3-year course of immunotherapy with standardized cat or dog extracts in 32 children and adults with asthma caused by animal dander.
Thirty of the subjects could be reached with a questionnaire, 19 underwent bronchial allergen and histamine challenges, and four had only a histamine challenge. Specific IgE and IgG4 levels in serum were measured in those who underwent challenges.
Almost all subjects (26 of 30) reported no change (17 subjects) or increased tolerance (9 subjects) on exposure to cats or dogs. In contrast, 17 of the 19 who underwent allergen challenges had increased allergen sensitivity compared with when therapy was stopped (p < 0.01), and the results were no longer significantly different from before therapy was started. Mean provocative concentration of histamine causing a 20% fall in peak expiratory flow was, however, still higher than before therapy in the cat immunotherapy group (p < 0.01) and had not changed significantly during the follow-up period. In the dog immunotherapy group there was no significant change during or after therapy. Specific IgG4 had decreased, and specific IgE in serum had remained low and was comparable to the levels measured at the end of the study period.
Five years after stopping immunotherapy, objectively measured bronchial allergen sensitivity had increased and had approached pretreatment conditions. Asthma symptoms, according to patients' subjective evaluations, had continued to be mild in most patients, and bronchial histamine sensitivity had remained stable. These observations could reflect remaining effects of immunotherapy or the natural history of mild asthma.
开展了一项为期5年的随访研究,以调查32名因动物皮屑引发哮喘的儿童和成人接受为期3年的标准化猫或狗提取物免疫治疗后的疗效持续时间。
通过问卷调查联系到了30名受试者,其中19人接受了支气管过敏原和组胺激发试验,4人仅接受了组胺激发试验。对接受激发试验的受试者测定了血清中的特异性IgE和IgG4水平。
几乎所有受试者(30人中的26人)报告称,接触猫或狗后无变化(17名受试者)或耐受性增加(9名受试者)。相比之下,19名接受过敏原激发试验的受试者中,有17人在停止治疗后过敏原敏感性增加(p<0.01),结果与治疗开始前不再有显著差异。然而,猫免疫治疗组中,导致呼气峰值流速下降20%的组胺平均激发浓度仍高于治疗前(p<0.01),且在随访期间无显著变化。狗免疫治疗组在治疗期间及治疗后均无显著变化。特异性IgG4下降,血清中的特异性IgE一直较低,与研究期末测得的水平相当。
停止免疫治疗5年后,客观测量的支气管过敏原敏感性增加,并已接近治疗前状态。根据患者的主观评估,大多数患者的哮喘症状持续较轻,支气管组胺敏感性保持稳定。这些观察结果可能反映了免疫治疗的残留效应或轻度哮喘的自然病程。